You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 18, 2025

Gilteritinib fumarate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for gilteritinib fumarate and what is the scope of freedom to operate?

Gilteritinib fumarate is the generic ingredient in one branded drug marketed by Astellas and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Gilteritinib fumarate has seventy-seven patent family members in thirty-one countries.

One supplier is listed for this compound.

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for gilteritinib fumarate
Generic Entry Date for gilteritinib fumarate*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for gilteritinib fumarate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 1
City of Hope Medical CenterPhase 1
Children's Oncology GroupPhase 3

See all gilteritinib fumarate clinical trials

Paragraph IV (Patent) Challenges for GILTERITINIB FUMARATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
XOSPATA Tablets gilteritinib fumarate 40 mg 211349 1 2022-11-28

US Patents and Regulatory Information for gilteritinib fumarate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas XOSPATA gilteritinib fumarate TABLET;ORAL 211349-001 Nov 28, 2018 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Astellas XOSPATA gilteritinib fumarate TABLET;ORAL 211349-001 Nov 28, 2018 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Astellas XOSPATA gilteritinib fumarate TABLET;ORAL 211349-001 Nov 28, 2018 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Astellas XOSPATA gilteritinib fumarate TABLET;ORAL 211349-001 Nov 28, 2018 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for gilteritinib fumarate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2428508 2090007-2 Sweden ⤷  Try for Free PRODUCT NAME: GILTERITINIB OR A SALT THEROF; REG. NO/DATE: EU/1/19/1399 20191028
2428508 PA2020002 Lithuania ⤷  Try for Free PRODUCT NAME: GILTERITINIBAS; REGISTRATION NO/DATE: EU/1/19/1399 20191024
2428508 301028 Netherlands ⤷  Try for Free PRODUCT NAME: GILTERITINIB OF EEN ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/19/13177 20191028
2428508 2020001 Norway ⤷  Try for Free PRODUCT NAME: GILTERITINIB ELLER ET SALT DERAV; REG. NO/DATE: EU/1/19/1399 20191030
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory for Gilteritinib Fumarate

Introduction

Gilteritinib fumarate, marketed as Xospata, is a significant advancement in the treatment of acute myeloid leukemia (AML) with FLT3 mutations. This article delves into the market dynamics and financial trajectory of gilteritinib, highlighting its impact, market size, and future projections.

Mechanism and Clinical Use

Gilteritinib fumarate is a pyrazinecarboxamide derivative that inhibits FLT3 and other receptor tyrosine kinases, particularly effective against FLT3-activating mutations in AML. It is used to treat adult patients with relapsed or refractory (R/R) FLT3 mutation-positive AML[2][4][5].

Market Size and Growth

The global FLT3 inhibitors market, which includes gilteritinib, was valued at USD 487.53 million in 2023 and is expected to reach USD 1,234.03 million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 10.87% during the forecast period (2024-2032)[3].

Regional Market Share

  • North America: This region is the largest shareholder in the global FLT3 inhibitors market, anticipated to grow at a CAGR of 14.41% during the forecast period. The U.S. and Canada dominate this market due to high acceptance rates among patients and physicians, as well as significant investments in research and development[3].
  • Europe: Expected to grow at a CAGR of 14.04%, Europe is another key market. Countries like Germany, France, the U.K., Italy, and Spain are actively involved in enhancing FLT3 mutated cancer treatments through extensive research[3].
  • Emerging Markets: Regions such as Asia-Pacific, Middle East and Africa, and Latin America are expected to be highly lucrative in the future due to the increasing demand for targeted therapeutics and the need for better access to these treatments in low- and middle-income economies[3].

Financial Impact on Health Plans

A budget impact analysis from a US payer's perspective indicates that the introduction of gilteritinib has a minimal budget impact. In a hypothetical health plan with 1 million members, the total plan budget increased by $663,795 in the first year, with a per-member-per-month (PMPM) cost increase of $0.055. In subsequent years, as the market share of gilteritinib increased to 45%, the total plan budget impact rose to $1,078,371 and $1,087,230, respectively, with PMPM costs increasing to $0.090 and $0.091[1].

Key Drivers of Market Growth

  • Increasing Prevalence of AML: The growing incidence of AML worldwide drives the demand for effective targeted therapies like FLT3 inhibitors[3].
  • Advancements in Research and Development: Continuous improvements in the research and development of targeted drugs for treating cancers with FLT3-positive mutations are a significant driver. Companies like Astellas Pharma Inc. are at the forefront of these advancements[3][4].
  • Regulatory Approvals: Gilteritinib has been approved in several countries, including the U.S., Canada, Japan, Europe, and China, which has expanded its market reach[3][4].

Competitive Landscape

The global FLT3 inhibitors market is dominated by Type 1 FLT3 inhibitors, with Xospata (gilteritinib) and Rydapt (midostaurin) being the primary products. Xospata, developed by Astellas Pharma Inc., is a second-generation Type 1 tyrosine kinase inhibitor with exclusive rights for manufacture and commercialization worldwide[3].

Challenges and Limitations

  • Access in Emerging Economies: Despite the growing demand, there is limited access to these drugs in low- and middle-income economies, which hampers market growth in these regions[3].
  • Regulatory and Clinical Assumptions: The financial impact and market dynamics are contingent upon various assumptions, including regulatory approvals, clinical guidelines, and market research data[1].

Future Projections

The global FLT3 inhibitors market is poised for significant growth, driven by the increasing prevalence of AML and advancements in targeted therapies. As research and development continue to advance, the market is expected to expand, particularly in emerging regions.

"The global FLT3 inhibitors market size was valued at USD 487.53 million in 2023 and is expected to reach USD 1,234.03 million in 2032, growing at a CAGR of 10.87% over the forecast period (2024-32)"[3].

Key Takeaways

  • Gilteritinib fumarate is a crucial drug in the treatment of R/R FLT3 mutation-positive AML.
  • The global FLT3 inhibitors market is growing rapidly, driven by increasing AML prevalence and advancements in targeted therapies.
  • North America and Europe are the largest markets, with emerging regions offering significant future growth opportunities.
  • The financial impact on health plans is minimal, despite the increasing market share of gilteritinib.
  • Access to these drugs in low- and middle-income economies remains a challenge.

FAQs

What is gilteritinib fumarate used for?

Gilteritinib fumarate, marketed as Xospata, is used to treat adult patients with relapsed or refractory (R/R) FLT3 mutation-positive acute myeloid leukemia (AML)[2][4][5].

How does gilteritinib fumarate work?

Gilteritinib fumarate inhibits FLT3 and other receptor tyrosine kinases, particularly effective against FLT3-activating mutations in AML[2][4][5].

What is the current market size of the global FLT3 inhibitors market?

The global FLT3 inhibitors market was valued at USD 487.53 million in 2023[3].

What is the projected growth rate of the global FLT3 inhibitors market?

The market is expected to grow at a CAGR of 10.87% from 2024 to 2032[3].

Which regions are expected to be highly lucrative for FLT3 inhibitors in the future?

Emerging regions such as Asia-Pacific, Middle East and Africa, and Latin America are expected to be highly lucrative markets in the future[3].

Last updated: 2024-12-23

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.